BIO.News Newsletter

We're running close to 5 minutes today (980 words), but we promise it's a good one. First, we're taking a look at what the U.S. biotech industry is doing to find a vaccine or treatment for the Wuhan coronavirus. Then, we've got the details on a court case that brings us one step closer to more certainty for the biofuels industry. Why do these stories matter right now? Because when it comes to the scary things that keep us up at night, like the potential for a global epidemic or climate…

If you needed a reminder of the importance of washing your hands during flu season, researchers say it's one of the best things you can do right now to protect yourself against the Wuhan coronavirus, reports the New York Times. (And yes, we'll be first in line to get a vaccine when one of our industry's innovators creates it.)  The virus isn't the only bad news today: Trump's reigniting plans for an international price index for drugs, and corporations are increasingly concerned about the…

In case you need some weekend reading, here are 815 words on the state of play on drug pricing and where things stand in the election, which you can read in just about 4 minutes. We'll see you (and the House) on Monday.

In case you missed it, it’s One Health Awareness Month—and since things are a bit slow in Washington with impeachment taking over, we’re doing a Good Day BIO takeover to tell you more about this initiative and why it’s important.

Day 2 of the impeachment trial is taking over Washington – but we're still super concerned about superbugs, and also revisiting Trump's recent comments to farmers and what they mean. Here are 695 words, 3 minutes, 28 seconds.

America’s third-ever impeachment trial begins…and POTUS is hangin' in the Swiss Alps.  While Washington’s focused on impeachment, we're taking a look at Trump's speech at Davos as well as new health care spending data, in 819 words, or 2 minutes, 59 seconds. 

Today’s Martin Luther King Jr. Day, and the federal government is closed to honor his legacy. But while we’re taking a breather from the news grind in Washington, science doesn’t stop—so we’re taking the opportunity to give you a look at what to expect in state legislatures this year, from Patrick J. Plues, BIO’s VP of State Government Affairs. We’ll be back tomorrow with the usual daily news.

We’re closing out the week with the details of an obscure court case in Delaware that could have a huge impact on biotechs, as well as a look at one researcher’s work to feed the world, in 766 words, or 3 minutes, 49 seconds. On Monday, we’re off to honor Martin Luther King Jr., but we’ll be publishing a special edition with a look at what to expect in the state legislatures in 2020. We’ll be back to regularly scheduled programing on Tuesday.

We’re closing out the week with the details of an obscure court case in Delaware that could have a huge impact on biotechs, as well as a look at one researcher’s work to feed the world, in 766 words, or 3 minutes, 49 seconds. On Monday, we’re off to honor Martin Luther King Jr., but we’ll be publishing a special edition with a look at what to expect in the state legislatures in 2020. We’ll be back to regularly scheduled programing on Tuesday.

Some positive news today for the future of biotech trade and investment. First, the United States and China signed the “phase one” agreement, and we have details on what it means for biotech. Then, we take a look at the final CFIUS regulations, which, thanks to our advocacy work, turned out to be much better for the industry and our ability to attract investment in new cures. Here are 771 words, which you can read in 3 minutes, 51 seconds.